Popular Articles

Human Genome Sciences And GlaxoSmithKline Announce Positive Phase 3 Study Results For BENLYSTA(TM) In Systemic Lupus Erythematosus
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that belimumab plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
generic viagra online
Clinical Study Shows Value Of Nexstim's Navigated Brain Stimulation (NBS) In Eloquent Cortex Surgery
Nexstim Oy, a medical device company developing non-invasive brain diagnostics and therapy technologies, announces presentation of the abstract "TMS as a part of multimodal management of safe glioma resection in the motor cortex" at the 60th Annual Meeting of the German Society of Neurosurgery.
News of the day
Bankruptcies Linked To Illness, Medical Bills In Nearly Two-Thirds Of Cases
Medical problems contributed to nearly two-thirds (62.1 percent) of all bankruptcies in 2007, according to a study in the August issue of the American Journal of Medicine that will be published online Thursday. The data were collected prior to the current economic downturn and hence likely understate the current burden of financial suffering. Between 2001 and 2007, the proportion of all bankruptcies attributable to medical problems rose by 49.6 percent. The authors" previous 2001 findings have been widely cited by policy leaders, including President Obama.
Health Insurance

Obama Nominates Human Genome Veteran To Lead NIH

Dr. Francis S. Collins, the Yale-educated, guitar-strumming physician and geneticist who led the Human Genome Project, was nominated Wednesday to head the National Institutes of Health, the New York Times reports. "Dr. Collins"s selection, which had been rumored for weeks, was praised by top scientists and research advocacy organizations for whom the health institute is a crucial patron," the Times reports. He is expected to sail through Senate confirmation. Collins has, however, earned skepticism in addition to praise. Some in the scientific community object to his religiousness and see his work as a kind of evangelism: "He wrote a book called "The Language of God," and he has given many talks and interviews in which he described his conversion to Christianity as a 27-year-old medical student." Another criticism is that, while managing the Human Genome Project, he over-inflated expectations, and then delivered little return - in terms of practical medical breakthroughs - on the massive investment when unexpected "scientific hurdles" emerged (Harris, 7/8). However, science continues to pursue personalized medicine based on genomics. "[T]he true power of genetics, he told a meeting of scientists in Washington last month, has yet to be realized as researchers eventually learn enough to provide customized predictions of which diseases really threaten an individual, and personalized care to respond," The Associated Press/Wall Street Journal report. "His groundbreaking work has changed the very ways we consider our health and examine disease," President Obama said when announcing the nomination (7/8). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):